BMO Capital raised the firm’s price target on Neurocrine (NBIX) to $115 from $96 but keeps a Market Perform rating on the shares after its Q1 results. The company’s better-than-expected Crenessity revenues are likely to benefit shares near term, but Ingrezza 2025 commercial dynamics present challenges, the analyst tells investors in a research note, adding that to hit Ingrezza’s 2025 guide requires a change in the asset’s current growth trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $130 from $115 at Wedbush
- Neurocrine price target raised to $145 from $137 at RBC Capital
- Promising Growth Trajectory for Neurocrine: Buy Rating Justified by Strong Drug Performance and Innovative Trials
- Neurocrine price target raised to $152 from $137 at UBS
- Neurocrine price target raised to $165 from $155 at Guggenheim